Survival predictors of radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the real-life.
Vincenzo MarottaDomenico RoccoAnna CroccoMaria Grazia DeianaRuggero MartinelliFrancesca Di GennaroMariafelicia ValerianiLuca ValvanoAlessia CaleoLuciano PezzulloAntongiulio FaggianoMario VitaleSalvatore MontiPublished in: The Journal of clinical endocrinology and metabolism (2024)
RR-DTC with good performance status and RAI-avid disease obtain the highest clinical benefit from lenvatinib. After treatment initiation, objective response was the only independent survival predictor.
Keyphrases